Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.53 |
| ▸ | SFRP1 | Q8N474 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616480 | 0.92 | SFRP1 (0.58) | TBXAS1SFRP1NAMPTMEN1KMT2A | |
| SCHEMBL4616468 | 0.88 | HTT (0.60) | SFRP1TAAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4617446 | 0.88 | TAAR1 (0.63) | SFRP1TAAR1ALDH1A1 | |
| SCHEMBL4619248 | 0.84 | TBXAS1 (0.53) | TBXAS1SFRP1TAAR1NAMPTMEN1 | |
| SCHEMBL4617416 | 0.81 | RAB9A (0.49) | SFRP1TAAR1HTT | |
| SCHEMBL4616698 | 0.81 | SFRP1 (0.72) | SFRP1TAAR1ALDH1A1HTT | |
| SCHEMBL4618264 | 0.81 | TDP1 (0.62) | SFRP1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4617716 | 0.78 | TBXAS1 (0.51) | TBXAS1SFRP1TAAR1NAMPTMEN1 | |
| SCHEMBL4618242 | 0.76 | SFRP1 (0.58) | TBXAS1SFRP1NAMPTLMNA | |
| SCHEMBL4639242 | 0.76 | ALDH1A1 (0.56) | SFRP1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | TBXAS1 2485/4885SFRP1 1/4885TAAR1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.